{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Defined as a patient who achieves a best response of partial response or complete response on the study. Confidence intervals will be constructed using the Wilson score interval method.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Palbociclib)"}],"paramType":"NUMBER","populationDescription":"Three patients did not receive any protocol therapy and are excluded from this analysis.","reportingStatus":"POSTED","timeFrame":"From enrollment to the end of treatment, up to 2 years","title":"Objective Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}